Grant ID RP150416
Awarded On February 18, 2015
Title Translational Investigations On Fenretinide and Safingol For Pediatric Cancer Use
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Cancer in Children and Adolescents
Institution/Organization Texas Tech University Health Sciences Center
Principal Investigator/Program Director Barry J Maurer
Cancer Sites Childhood and Adolescent
Contracted Amount $1,999,415
Lay Summary

We are developing a new kind of chemotherapy to fight pediatric cancers resistant to current therapies. This new chemotherapy uses high doses of a drug, called fenretinide, to increase certain toxic waxes, called dihydroceramides, in cancer cells and kill them. Because these waxes do not increase in normal cells, fenretinide is well-tolerated clinically. Using new formulations of fenretinide, we have been able to reduce, even eliminate, pediatric neuroblastoma cancer cells in some children in early clinical trials. We will now try to further increase the killing power of fenretinide by combining it with an artificial wax, called safingol. In the laboratory, when fenretinide-induced waxes mee...

Read More